Conference Proceedings

Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).

Deborah Smith, Kristy Robledo, Sonia Yip, Michelle Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally E Baron-Hay, Catherine M Shannon, Jermaine Coward, Philip James Beale, Geraldine Goss, Tarek Meniawy, Janine Margaret Lombard, Amanda B Spurdle, John Andrews, Martin R Stockler, Linda R Mileshkin, Yoland Catherine Antill

JOURNAL OF CLINICAL ONCOLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

Abstract

5584 Background: Activity of durvalumab in patients with deficient mismatch repair (dMMR) advanced endometrial carcinoma (EC) was confirmed in the PHAEDRA trial (ANZGOG 1601). This study investigated the association between immune biomarkers and clinical outcomes in PHAEDRA. Methods: Formalin-fixed paraffin embedded sections immunohistochemically stained for PD-L1 using the Ventana platform, were with matched H&E slides scored independently by two pathologists according to the Ventana PD-L1 (SP263) algorithm for urothelial carcinoma (UC). Immune biomarkers assessed were PD-L1 staining of tumor cells (TCP) and immune cells (IC), and presence of tumor-associated immune cells (ICP). Results: S..

View full abstract

University of Melbourne Researchers